Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial (2015)
- Authors:
- USP affiliated authors: SAPIENZA, MARCELO TATIT - FM ; BUCHPIGUEL, CARLOS ALBERTO - FM ; WATANABE, TOMOCO - FM
- Unidade: FM
- DOI: 10.1097/RLU.0000000000000840
- Subjects: DOSIMETRIA; IODO; MEDICINA NUCLEAR (TRATAMENTO); DOENÇA DE GRAVES; GLÂNDULA TIREOIDE; HIPERTIREOIDISMO
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2015
- Source:
- Título do periódico: Clinical Nuclear Medicine
- ISSN: 0363-9762
- Volume/Número/Paginação/Ano: v. 40, n. 9, p. 715-719, 2015
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SAPIENZA, Marcelo Tatit et al. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial. Clinical Nuclear Medicine, v. 40, n. 9, p. 715-719, 2015Tradução . . Disponível em: https://doi.org/10.1097/RLU.0000000000000840. Acesso em: 11 jun. 2024. -
APA
Sapienza, M. T., Coura-Filho, G. B., Willegaignon, J., Watanabe, T., Duarte, P. S., & Buchpiguel, C. A. (2015). Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial. Clinical Nuclear Medicine, 40( 9), 715-719. doi:10.1097/RLU.0000000000000840 -
NLM
Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial [Internet]. Clinical Nuclear Medicine. 2015 ; 40( 9): 715-719.[citado 2024 jun. 11 ] Available from: https://doi.org/10.1097/RLU.0000000000000840 -
Vancouver
Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric Variables Related to Outcome After Treatment of Graves' Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial [Internet]. Clinical Nuclear Medicine. 2015 ; 40( 9): 715-719.[citado 2024 jun. 11 ] Available from: https://doi.org/10.1097/RLU.0000000000000840 - Visualization of Lymph Nodal and Hepatic Metastases of Medullary Thyroid Carcinoma on 18F-Fluoride PET/CT
- Estudos diagnósticos com análogos da somatostatina
- Ga-68-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours
- Preliminary Comparison of PET/CT Studies Performed After Intravenous and Oral Administration of 18F-Fluoride
- Pediatric 131I-MIBG therapy for neuroblastoma: whole-Body 131I-MIBG clearance, radiation doses to patients, family caregivers, medical staff, and radiation safety measures
- Bone and Calcified Soft Tissue Metastases of Medullary Thyroid Carcinoma Better Characterized on F-18-Fluoride PET/CT than on Ga-68-Dotatate PET/CT
- Brain metastasis of medullary thyroid carcinoma without macroscopic calcification detected first on 68Ga-Dotatate and then on 18F-Fluoride PET/CT
- Cintilografia hepática com hemácias marcadas para a avaliação de hemangioma hepatico
- PET/CT no câncer de fígado e vias biliares
- Correlação entre volume tireoidiano determinado pelo método de ultrassonografia versus cintilografia e sua implicação em cálculos dosimétricos na terapia com radioiodo na doença de Graves
Informações sobre o DOI: 10.1097/RLU.0000000000000840 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
